Universitätsklinikum Carl-Gustav-Carus an der Technischen Universität Dresden

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer	Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma	Active, not recruiting	Phase 2	2026-05-13		NCT04274426

Clinical trials